We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Assertio (ASRT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Assertio is one of 924 companies in the Medical group. The Medical group currently sits at #9 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 110% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ASRT has returned about 54.4% since the start of the calendar year. In comparison, Medical companies have returned an average of -6.5%. As we can see, Assertio is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is BrightSpring Health Services, Inc. (BTSG - Free Report) . The stock is up 12.4% year-to-date.
In BrightSpring Health Services, Inc.'s case, the consensus EPS estimate for the current year increased 15.2% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Assertio belongs to the Medical - Drugs industry, a group that includes 143 individual companies and currently sits at #93 in the Zacks Industry Rank. This group has lost an average of 5.2% so far this year, so ASRT is performing better in this area.
On the other hand, BrightSpring Health Services, Inc. belongs to the Medical Services industry. This 66-stock industry is currently ranked #94. The industry has moved -10.6% year to date.
Investors interested in the Medical sector may want to keep a close eye on Assertio and BrightSpring Health Services, Inc. as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Assertio (ASRT - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Assertio is one of 924 companies in the Medical group. The Medical group currently sits at #9 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 110% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ASRT has returned about 54.4% since the start of the calendar year. In comparison, Medical companies have returned an average of -6.5%. As we can see, Assertio is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is BrightSpring Health Services, Inc. (BTSG - Free Report) . The stock is up 12.4% year-to-date.
In BrightSpring Health Services, Inc.'s case, the consensus EPS estimate for the current year increased 15.2% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Assertio belongs to the Medical - Drugs industry, a group that includes 143 individual companies and currently sits at #93 in the Zacks Industry Rank. This group has lost an average of 5.2% so far this year, so ASRT is performing better in this area.
On the other hand, BrightSpring Health Services, Inc. belongs to the Medical Services industry. This 66-stock industry is currently ranked #94. The industry has moved -10.6% year to date.
Investors interested in the Medical sector may want to keep a close eye on Assertio and BrightSpring Health Services, Inc. as they attempt to continue their solid performance.